Doctors are diagnosing more patients as US market normalizes, says Lundbeck CEO
The Covid-19 pandemic has been tough on several of the drugs sold by Lundbeck but the clouds seem to be lifting and recovery might be on the horizon, making Lundbeck ramp up marketing efforts of migraine drug Vyepti.
by marketwire, translated by daniel pedersen
Lundbeck's newest drugs have been received well, not least on the important US market, on which sales growth of key products appear to have forward momentum.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck presents positive results from migraine drug trial
For subscribers
